AbCellera Biologics Inc (NASDAQ:ABCL) Reports Mixed Q3 2025 Results with Revenue Beat and Wider Loss

AbCellera Biologics Inc (NASDAQ:ABCL) has reported its financial results for the third quarter of 2025, delivering a mixed performance that saw revenue exceed expectations while its net loss widened, contributing to negative after-hours price movement.

Earnings and Revenue Versus Estimates

The company's top-line performance provided a positive surprise relative to analyst forecasts, while its bottom-line results fell short of consensus estimates.

• Revenue: The company reported total revenue of $9.0 million for Q3 2025, a significant increase from the $6.5 million reported in the same quarter last year. This figure substantially surpassed the analyst revenue estimate of approximately $6.03 million.
• Earnings Per Share (EPS): AbCellera posted a net loss of $57.1 million, or a loss of $0.19 per share. This compares to a net loss of $51.1 million, or $0.17 per share, in Q3 2024. The reported EPS was worse than the analyst estimate for a loss of $0.17 per share.

Market Reaction

The market's immediate reaction to the earnings release was negative. Following the announcement, AbCellera's stock was down approximately 3.75% in after-hours trading. This suggests investor focus may have settled on the widening net loss and higher-than-anticipated EPS loss, overshadowing the strong revenue beat. The stock had already been under some pressure, showing negative performance over the past month.

Business Highlights and Operational Progress

Beyond the financial figures, the earnings press release highlighted several key operational milestones that the company is emphasizing as part of its long-term strategy.

• Clinical Pipeline: The company's two lead internal programs, ABCL635 and ABCL575, continue to progress through Phase 1 clinical trials.
• Platform and Infrastructure: AbCellera noted the successful start of activities at its new clinical manufacturing facility and the substantial completion of its platform investments during the quarter.
• Key Business Metrics: The company reported growth in its cumulative partnership and development metrics.
  • Partner-initiated program starts with downstreams reached 103, up from 95 a year ago.
  • Molecules in the clinic increased to 18, up from 14 a year ago.
• Financial Position: The company ended the quarter with a strong liquidity position, reporting $523 million in cash, cash equivalents, and marketable securities. With approximately $159 million in available non-dilutive government funding, total available liquidity stands at about $680 million.

Looking Ahead

The company did not provide a specific financial outlook for the coming quarters or the full year in its press release. For context, analysts are currently estimating a Q4 2025 revenue of approximately $6.37 million and an EPS loss of $0.17. For the full 2025 fiscal year, the consensus estimates project a loss of $0.62 per share on revenue of $33.73 million. The absence of company-provided guidance is a neutral factor and does not inherently explain the negative market reaction, which appears more directly tied to the quarterly earnings miss.

For a detailed look at historical earnings, future estimates, and analyst projections, you can review the data here.

Disclaimer: This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.